L-Carnitine Combination for Chronic Venous Insufficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic venous insufficiency (CVI) are inadequate in addressing the underlying venous issues and their complications, such as swelling, inflammation, and varicose veins, as they often rely on compression stockings, injections, or surgical procedures, which may not fully alleviate symptoms or prevent recurrence.
Innovation Solution
A combination composition comprising L-carnitine or propionyl-L-carnitine, troxerutine, and hesperidine, which exhibit a synergistic effect in improving venous health by enhancing circulation, reducing inflammation, and preventing venous hypertension, administered orally or topically to treat and prevent CVI and its complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compression stockings are used to treat CVI, then venous pressure is reduced and circulation is improved, but patient compliance is poor and symptoms recur upon removal
Solution Approach 1:
The patent replaces the mechanical compression system (stockings) with a biochemical system using L-carnitine and propionyl-L-carnitine that work internally to improve venous function, eliminating the need for external mechanical compression devices that require patient compliance
Solution Approach 2:
The invention enables the body's own systems to treat CVI by using carnitine derivatives that enhance endogenous energy metabolism in vein walls and improve autonomous venous pump function, allowing the body to self-regulate venous pressure without external devices
2Reliability
If surgical procedures are performed to correct CVI, then venous valve function is restored, but treatment complexity and recovery time increase
Solution Approach 1:
The patent uses oral supplementation of L-carnitine and propionyl-L-carnitine as a simple, non-invasive, temporary treatment that accumulates in the body to produce sustained effects, replacing complex surgical interventions with a straightforward supplementation approach
Solution Approach 2:
The invention changes the biochemical parameters within vein walls by increasing carnitine levels, which improves energy metabolism and venous muscle function, thereby restoring venous valve function through biochemical modification rather than surgical mechanical repair
3Reliability
If L-carnitine and propionyl-L-carnitine are used together, then synergistic effect is achieved in improving venous function, but formulation complexity increases
Solution Approach 1:
The patent combines L-carnitine and propionyl-L-carnitine in a single formulation where the two compounds work synergistically - L-carnitine provides baseline metabolic support while propionyl-L-carnitine enhances energy production and has anti-inflammatory effects, creating a unified treatment approach
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both L-carnitine and propionyl-L-carnitine along with excipients, where the combination of active ingredients produces synergistic effects that exceed the sum of individual components, analogous to composite materials achieving superior properties
Data Source
AI summary
It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and /or treatment of chronic venous diseases.